Tandem Diabetes Care (TNDM) EBIAT (2016 - 2025)
Historic EBIAT for Tandem Diabetes Care (TNDM) over the last 13 years, with Q3 2025 value amounting to -$21.2 million.
- Tandem Diabetes Care's EBIAT rose 897.17% to -$21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$203.4 million, marking a year-over-year decrease of 6040.61%. This contributed to the annual value of -$96.0 million for FY2024, which is 5686.42% up from last year.
- Per Tandem Diabetes Care's latest filing, its EBIAT stood at -$21.2 million for Q3 2025, which was up 897.17% from -$52.4 million recorded in Q2 2025.
- Tandem Diabetes Care's EBIAT's 5-year high stood at $10.8 million during Q4 2021, with a 5-year trough of -$130.6 million in Q1 2025.
- For the 5-year period, Tandem Diabetes Care's EBIAT averaged around -$31.7 million, with its median value being -$23.3 million (2024).
- Per our database at Business Quant, Tandem Diabetes Care's EBIAT soared by 16158.59% in 2021 and then crashed by 94518.47% in 2022.
- Tandem Diabetes Care's EBIAT (Quarter) stood at $10.8 million in 2021, then tumbled by 246.67% to -$15.9 million in 2022, then crashed by 89.26% to -$30.0 million in 2023, then surged by 102.52% to $755000.0 in 2024, then plummeted by 2903.31% to -$21.2 million in 2025.
- Its last three reported values are -$21.2 million in Q3 2025, -$52.4 million for Q2 2025, and -$130.6 million during Q1 2025.